CovidStanfordV1, Main, Exploration, bibRecord, 000147

What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.

Identifieur interne : 000147 ( Main/Exploration ); précédent : 000146; suivant : 000148

What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.

Auteurs : Sunnie Y. Wong [États-Unis] ; Aleah L. Brubaker [États-Unis] ; Aileen X. Wang [États-Unis] ; Adetokunbo A. Taiwo [États-Unis] ; Marc L. Melcher [États-Unis]

Source :

Clinical transplantation [ 1399-0012 ] ; 2020.

RBID : pubmed:32446267

Descripteurs français

English descriptors

KwdEn :
- Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Cardiovascular Diseases (complications), Cardiovascular Diseases (therapy), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Coronavirus Infections (therapy), Humans (MeSH), Organ Transplantation (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnosis), Pneumonia, Viral (therapy), Renin-Angiotensin System (physiology), SARS-CoV-2 (MeSH).
MESH :
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- complications : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- physiology : Renin-Angiotensin System.
- therapy : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Organ Transplantation, Pandemics, SARS-CoV-2.

Abstract

The data on the outcomes of solid organ transplant recipients who have contracted coronavirus disease 2019 (COVID-19) are still emerging. Kidney transplant recipients are commonly prescribed renin-angiotensin-aldosterone system (AAS) inhibitors given the prevalence of hypertension, diabetes, and cardiovascular disease. As the angiotensin-converting enzyme 2 (ACE2) facilitates the entry of coronaviruses into target cells, there have been hypotheses that preexisting use of renin-angiotensin-aldosterone system (RAAS) inhibitors may increase the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Given the common use of RAAS inhibitors among solid organ transplant recipients, we sought to review the RAAS cascade, the mechanism of SARS-CoV-2 entry, and pertinent data related to the effect of RAAS inhibitors on ACE2 to guide management of solid organ transplant recipients during the COVID-19 pandemic. At present, there is no clear evidence to support the discontinuation of RAAS inhibitors in solid organ transplant recipients during the COVID-19 pandemic.

DOI: 10.1111/ctr.13991
PubMed: 32446267
PubMed Central: PMC7267091

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000688
to stream Main, to step Curation: 000688

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.</title>
<author><name sortKey="Wong, Sunnie Y" sort="Wong, Sunnie Y" uniqKey="Wong S" first="Sunnie Y" last="Wong">Sunnie Y. Wong</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Brubaker, Aleah L" sort="Brubaker, Aleah L" uniqKey="Brubaker A" first="Aleah L" last="Brubaker">Aleah L. Brubaker</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Aileen X" sort="Wang, Aileen X" uniqKey="Wang A" first="Aileen X" last="Wang">Aileen X. Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Taiwo, Adetokunbo A" sort="Taiwo, Adetokunbo A" uniqKey="Taiwo A" first="Adetokunbo A" last="Taiwo">Adetokunbo A. Taiwo</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Melcher, Marc L" sort="Melcher, Marc L" uniqKey="Melcher M" first="Marc L" last="Melcher">Marc L. Melcher</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32446267</idno>
<idno type="pmid">32446267</idno>
<idno type="doi">10.1111/ctr.13991</idno>
<idno type="pmc">PMC7267091</idno>
<idno type="wicri:Area/Main/Corpus">000688</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000688</idno>
<idno type="wicri:Area/Main/Curation">000688</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000688</idno>
<idno type="wicri:Area/Main/Exploration">000688</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.</title>
<author><name sortKey="Wong, Sunnie Y" sort="Wong, Sunnie Y" uniqKey="Wong S" first="Sunnie Y" last="Wong">Sunnie Y. Wong</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Brubaker, Aleah L" sort="Brubaker, Aleah L" uniqKey="Brubaker A" first="Aleah L" last="Brubaker">Aleah L. Brubaker</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Aileen X" sort="Wang, Aileen X" uniqKey="Wang A" first="Aileen X" last="Wang">Aileen X. Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Taiwo, Adetokunbo A" sort="Taiwo, Adetokunbo A" uniqKey="Taiwo A" first="Adetokunbo A" last="Taiwo">Adetokunbo A. Taiwo</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Melcher, Marc L" sort="Melcher, Marc L" uniqKey="Melcher M" first="Marc L" last="Melcher">Marc L. Melcher</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical transplantation</title>
<idno type="eISSN">1399-0012</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (therapeutic use)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Cardiovascular Diseases (complications)</term>
<term>Cardiovascular Diseases (therapy)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Humans (MeSH)</term>
<term>Organ Transplantation (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Renin-Angiotensin System (physiology)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term>
<term>Maladies cardiovasculaires (complications)</term>
<term>Maladies cardiovasculaires (thérapie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Système rénine-angiotensine (physiologie)</term>
<term>Transplantation d'organe (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term>
<term>Angiotensin-Converting Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Système rénine-angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Renin-Angiotensin System</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies cardiovasculaires</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term>
<term>Infections à coronavirus</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
<term>Maladies cardiovasculaires</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Organ Transplantation</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Transplantation d'organe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The data on the outcomes of solid organ transplant recipients who have contracted coronavirus disease 2019 (COVID-19) are still emerging. Kidney transplant recipients are commonly prescribed renin-angiotensin-aldosterone system (AAS) inhibitors given the prevalence of hypertension, diabetes, and cardiovascular disease. As the angiotensin-converting enzyme 2 (ACE2) facilitates the entry of coronaviruses into target cells, there have been hypotheses that preexisting use of renin-angiotensin-aldosterone system (RAAS) inhibitors may increase the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Given the common use of RAAS inhibitors among solid organ transplant recipients, we sought to review the RAAS cascade, the mechanism of SARS-CoV-2 entry, and pertinent data related to the effect of RAAS inhibitors on ACE2 to guide management of solid organ transplant recipients during the COVID-19 pandemic. At present, there is no clear evidence to support the discontinuation of RAAS inhibitors in solid organ transplant recipients during the COVID-19 pandemic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32446267</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>34</Volume>
<Issue>7</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Clinical transplantation</Title>
<ISOAbbreviation>Clin Transplant</ISOAbbreviation>
</Journal>
<ArticleTitle>What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>e13991</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.13991</ELocationID>
<Abstract><AbstractText>The data on the outcomes of solid organ transplant recipients who have contracted coronavirus disease 2019 (COVID-19) are still emerging. Kidney transplant recipients are commonly prescribed renin-angiotensin-aldosterone system (AAS) inhibitors given the prevalence of hypertension, diabetes, and cardiovascular disease. As the angiotensin-converting enzyme 2 (ACE2) facilitates the entry of coronaviruses into target cells, there have been hypotheses that preexisting use of renin-angiotensin-aldosterone system (RAAS) inhibitors may increase the risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Given the common use of RAAS inhibitors among solid organ transplant recipients, we sought to review the RAAS cascade, the mechanism of SARS-CoV-2 entry, and pertinent data related to the effect of RAAS inhibitors on ACE2 to guide management of solid organ transplant recipients during the COVID-19 pandemic. At present, there is no clear evidence to support the discontinuation of RAAS inhibitors in solid organ transplant recipients during the COVID-19 pandemic.</AbstractText>
<CopyrightInformation>© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Sunnie Y</ForeName>
<Initials>SY</Initials>
<Identifier Source="ORCID">0000-0002-4872-6500</Identifier>
<AffiliationInfo><Affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brubaker</LastName>
<ForeName>Aleah L</ForeName>
<Initials>AL</Initials>
<Identifier Source="ORCID">0000-0003-4795-2562</Identifier>
<AffiliationInfo><Affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Aileen X</ForeName>
<Initials>AX</Initials>
<AffiliationInfo><Affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taiwo</LastName>
<ForeName>Adetokunbo A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo><Affiliation>Division of Nephrology, Dept. of Medicine, Stanford University, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Melcher</LastName>
<ForeName>Marc L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Denmark</Country>
<MedlineTA>Clin Transplant</MedlineTA>
<NlmUniqueID>8710240</NlmUniqueID>
<ISSNLinking>0902-0063</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016377" MajorTopicYN="Y">Organ Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ACE2 receptor</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">renin-angiotensin-aldosterone inhibitors</Keyword>
<Keyword MajorTopicYN="Y">solid organ transplant</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32446267</ArticleId>
<ArticleId IdType="doi">10.1111/ctr.13991</ArticleId>
<ArticleId IdType="pmc">PMC7267091</ArticleId>
</ArticleIdList>
<ReferenceList><Title>REFERENCES</Title>
<Reference><Citation>Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534.</Citation>
</Reference>
<Reference><Citation>Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97(6):1076-1082.</Citation>
</Reference>
<Reference><Citation>Montagud-Marrahi E, Cofan F, Torregrosa J-V, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15970</Citation>
</Reference>
<Reference><Citation>Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020. https://doi.org/10.1056/nejmc2011117</Citation>
</Reference>
<Reference><Citation>Coates PT, Wong G, Drueke T, et al. Early experience with COVID-19 in kidney transplantation. Kidney Int. 2020;97(6):1074-1075.</Citation>
</Reference>
<Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation>
</Reference>
<Reference><Citation>Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.</Citation>
</Reference>
<Reference><Citation>Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683</Citation>
</Reference>
<Reference><Citation>Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.</Citation>
</Reference>
<Reference><Citation>Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.</Citation>
</Reference>
<Reference><Citation>Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781-782.</Citation>
</Reference>
<Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.</Citation>
</Reference>
<Reference><Citation>Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ. 2020;369:m1313.</Citation>
</Reference>
<Reference><Citation>Brown JD. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020;8(5):e28.</Citation>
</Reference>
<Reference><Citation>Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004;1:42-47.</Citation>
</Reference>
<Reference><Citation>Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985-2991.</Citation>
</Reference>
<Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.</Citation>
</Reference>
<Reference><Citation>Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905-913.e7.</Citation>
</Reference>
<Reference><Citation>Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.</Citation>
</Reference>
<Reference><Citation>Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605-2610.</Citation>
</Reference>
<Reference><Citation>Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48:572-578.</Citation>
</Reference>
<Reference><Citation>Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci. 2012;123:649-658.</Citation>
</Reference>
<Reference><Citation>Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26:369-375; discussion 322-4.</Citation>
</Reference>
<Reference><Citation>Hamming I, van Goor H, Turner AJ, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol. 2008;93:631-638.</Citation>
</Reference>
<Reference><Citation>Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180-190.</Citation>
</Reference>
<Reference><Citation>Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol. 2012;351:208-219.</Citation>
</Reference>
<Reference><Citation>Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976.</Citation>
</Reference>
<Reference><Citation>Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296:F398-F405.</Citation>
</Reference>
<Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879.</Citation>
</Reference>
<Reference><Citation>Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens. 2004;22:1971-1976.</Citation>
</Reference>
<Reference><Citation>Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15:565-571.</Citation>
</Reference>
<Reference><Citation>Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19:1280-1287.</Citation>
</Reference>
<Reference><Citation>Ramchand J, Patel SK, Kearney LG, et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging. 2020;13:655-664.</Citation>
</Reference>
<Reference><Citation>Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One. 2018;13:e0198144.</Citation>
</Reference>
<Reference><Citation>Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15-21.</Citation>
</Reference>
<Reference><Citation>Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618-625.</Citation>
</Reference>
<Reference><Citation>Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol. 2008;3:491-504.</Citation>
</Reference>
<Reference><Citation>Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int. 2003;63:1187-1194.</Citation>
</Reference>
<Reference><Citation>Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int. 2009;22:1073-1080.</Citation>
</Reference>
<Reference><Citation>Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257-3262.</Citation>
</Reference>
<Reference><Citation>Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2017;69:78-86.</Citation>
</Reference>
<Reference><Citation>Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889-899.</Citation>
</Reference>
<Reference><Citation>Cheungpasitporn W, Thongprayoon C, Mao MA, Kittanamongkolchai W, Sathick IJJ, Erickson SB. The effect of renin-angiotensin system inhibitors on kidney allograft survival: a systematic review and meta-analysis. N Am J Med Sci. 2016;8:291-296.</Citation>
</Reference>
<Reference><Citation>Paoletti E, Bellino D, Marsano L, et al. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation. 2013;95:889-895.</Citation>
</Reference>
<Reference><Citation>Liao R-X, Lyu X-F, Tang W-J, Gao K. Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: a meta-analysis of randomized controlled trials. Clin Transplant. 2017;31.</Citation>
</Reference>
<Reference><Citation>Banasik M, Boratyńska M, Kościelska-Kasprzak K, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int. 2014;27:1029-1038.</Citation>
</Reference>
<Reference><Citation>Lefaucheur C, Viglietti D, Bouatou Y, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019;96:189-201.</Citation>
</Reference>
<Reference><Citation>Reinsmoen NL. Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation. Hum Immunol. 2013;74:1474-1477.</Citation>
</Reference>
<Reference><Citation>Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558-569.</Citation>
</Reference>
<Reference><Citation>D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020;26(6):832-834.</Citation>
</Reference>
<Reference><Citation>Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532-533.</Citation>
</Reference>
<Reference><Citation>Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020. https://doi.org/10.1056/NEJMc2011117</Citation>
</Reference>
<Reference><Citation>Zhang H, Chen Y, Yuan Q, et al. Identification of kidney transplant recipients with coronavirus disease 2019. Eur Urol. 2020;77(6):742-747.</Citation>
</Reference>
<Reference><Citation>Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant. 2020. https://doi.org/10.1111/ajt.15874</Citation>
</Reference>
<Reference><Citation>Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):135-136.</Citation>
</Reference>
<Reference><Citation>Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:8.</Citation>
</Reference>
<Reference><Citation>Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
<settlement><li>Stanford (Californie)</li>
</settlement>
<orgName><li>Université Stanford</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Wong, Sunnie Y" sort="Wong, Sunnie Y" uniqKey="Wong S" first="Sunnie Y" last="Wong">Sunnie Y. Wong</name>
</region>
<name sortKey="Brubaker, Aleah L" sort="Brubaker, Aleah L" uniqKey="Brubaker A" first="Aleah L" last="Brubaker">Aleah L. Brubaker</name>
<name sortKey="Melcher, Marc L" sort="Melcher, Marc L" uniqKey="Melcher M" first="Marc L" last="Melcher">Marc L. Melcher</name>
<name sortKey="Taiwo, Adetokunbo A" sort="Taiwo, Adetokunbo A" uniqKey="Taiwo A" first="Adetokunbo A" last="Taiwo">Adetokunbo A. Taiwo</name>
<name sortKey="Wang, Aileen X" sort="Wang, Aileen X" uniqKey="Wang A" first="Aileen X" last="Wang">Aileen X. Wang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000147 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000147 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32446267
   |texte=   What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32446267" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.

What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki